Medicine
Permanent URI for this communityhttp://repository.kln.ac.lk/handle/123456789/12
This repository contains the published and unpublished research of the Faculty of Medicine by the staff members of the faculty
Browse
7 results
Search Results
Item Quality of life of inflammatory bowel disease at diagnosis in 8 countries in Asia: The ACCESS study(Wiley Blackwell Scientific Publications, 2013) Ng, S.C.; Tang, W.; de Silva, H.J.; Mettananda, K.C.D.; Weerasinghe, S.K.; Ling, K.L.; Ho, L.; Ong, D.; Ooi, C.J.; Hilmi, I.; Goh, K.L.; Manatsathit, S.; Aniwan, S.; Pisespongsa, P.; Abdullah, M.; Zeng, Z.; Hu, P.; Chen, M.; Ouyang, Q.; Wang, Y.F.; WU, K.; Ng, K.K.; Yu, H.H.; Ching, J.; Sung, J.; Chan, F.K.OBJECTIVE: Health-related quality of life (QOL) is an important outcome measure in inflammatory bowel disease (IBD). QOL of Asian patients with IBD at presentation has not been studied. AIM: This study evaluates the QOL of IBD patients at diagnosis from an inception cohort across eight countries in Asia. METHODS: Health-related QOL was measured by the validated IBD Questionnaire (IBDQ) in patients with newly diagnosed IBD between 2011 and 2012. Disease activity was assessed by the Simple Clinical Colitis Activity Index and Harvey-Bradshaw index for ulcerative colitis (UC) and Crohn’s disease (CD), respectively. Demographic and disease characteristics were recorded. RESULTS: 284 incident IBD cases (CD 93; UC 147; IC 14) were included. Median age was 37 (IQR: 26–49). Median duration from symptom onset to diagnosis was 6 months (IQR:2– 24). Overall mean IBDQ score was 159 ± SEM 2.2 (Remission: IBQ≥170). The median IBDQ Score of South Asians (Thailand, Malaysia, Indonesia, Sri Lanka) (150; IQR:117–181) was significantly lower than the Han Chinese (Mainland China, Hong Kong, Singapore, Macau) (167; IQR:139–190; p = 0.003). IBD patients with active disease had significantly lower scores for all 4 dimensions of IBDQ (bowel, systemic, emotional and social functions) compared with those in remission (p < 0.001). Multiple regression analyses identified only disease activity index to be associated with variations in QOL (p < 0.001). There was no significant difference in QOL between patients with CD, UC or IC (p = 0.403). QOLwas not significantly affected by disease behavior for CD (B1, B2, B3, or perianal) but worsened with increasing mucosal involvement in UC (extensive > distal > proctitis; p = 0.014). QOL score was not affected by employment status, education level or smoking history. CONCLUSION: QOL is impaired in newly diagnosed IBD patients, and varies across ethnic groups in Asia. Active disease and more extensive disease are associated with worse QOL in IBD.Item The Asia Pacific Consensus Statements on Crohn's Disease Part 2: Management(Wiley-Blackwell, 2016) Ooi, C.J.; Hilmi, I.; Makharia, G.K.; Gibson, P.R.; Fock, K.M.; Ahuja, V.; Ling, K.L.; Lim, W.C.; Thia, K.T.; Wei, S.C.; Leung, W.K.; Koh, P.K.; Gearry, R.B.; Goh, K.L.; Ouyang, Q.; Sollano, J.; Manatsathit, S.; de Silva, H.J.; Rerknimitr, R.; Pisespongsa, P.; Abu Hassan, M.R.; Sung, J.; Hibi, T.; Boey, C.C.; Moran, N.; Leong, R.W.; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel DiseaseInflammatory bowel disease (IBD) was previously thought to be rare in Asia, but emerging data indicate rising incidence and prevalence of IBD in the region. The Asia Pacific Working Group on Inflammatory Bowel Disease was established in Cebu, Philippines, at the Asia Pacific Digestive Week conference in 2006 under the auspices of the Asian Pacific Association of Gastroenterology (APAGE) with the goal of developing best management practices, coordinating research and raising awareness of IBD in the region. The consensus group previously published recommendations for the diagnosis and management of ulcerative colitis (UC) with specific relevance to the Asia-Pacific region.1 The present consensus statements were developed following a similar process to address the epidemiology, diagnosis and management of Crohn's disease (CD). The goals of these statements are to pool the pertinent literature specifically highlighting relevant data and conditions in the Asia-Pacific region relating to the economy, health systems, background infectious diseases, differential diagnoses and treatment availability. It does not intend to be all-comprehensive and future revisions are likely to be required in this ever-changing field. This article is protected by copyright. All rights reserved.Item Asia Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease.The Asia-Pacific consensus on ulcerative colitis.(Wiley-Blackwell, 2010) Ooi, C.J.; Fock, K.M.; Makharia, G.K.; Goh, K.L.; Ling, K.L.; Hilmi, I.; Lim, W.C.; Kelvin, T.; Gibson, P.R.; Gearry, R.B.; Ouyang, Q.; Sollano, J.; Manatsathit, S.; Rerknimitr, R.; Wei, S.C.; Leung, W.K.; de Silva, H.J.; Leong, R.W.Item Management of ulcerative colitis(State Pharmaceuticals Corporation, 1998) de Silva, H.J.; Seneviratne, S.L.No abstract availableItem Optimum dose of olsalazine for maintaining remission in ulcerative colitis(British Medical Assosiation, 1994) Travis, S.P.L.; Tysk, C.; de Silva, H.J.; Sandberg-Gertzen, H.; Jewell, D.P.; Jarnerot, G.To evaluate the optimum dose of olsalazine for maintaining remission in ulcerative colitis, 198 patients in remission for more than three months were randomly assigned to receive 0.5 g, 1.0 g, or 2.0 g/day for 12 months. A dose-ranging effect was detected in the per protocol analysis, with remission rates of 60% (0.5 g), 70% (1.0 g), and 78% (2.0 g) (p = 0.03, trend in proportions). The higher dose was most effective in patients with proctitis (90% remission on 2 g/day, p = 0.03) or those in remission for less than 12 months before the trial (88% remission on 2 g/day, p = 0.0006). There was little dose-ranging effect in patients with extensive colitis or those in remission for more than 12 months. Diarrhoea necessitated treatment withdrawal in 12%. The optimal dose of olsalazine for maintaining remission in ulcerative colitis is 1 g/day. For patients with proctitis or recent relapse, 2 g/day may be preferable, although the dose seems to be less important in patients with more extensive disease or those in long term remissionItem Cytokine production by human colonic intraepithelial lymphocytes in controls and ulcerative colitis(Hindawi Publishing Cooperation, 1994) Hoang, P.; Dalton, H.R.; de Silva, H.J.; Jewell, D.P.Using an ELISA technique, concentrations of gamma-interferon and interleukin-2 were assayed in the supernatants of colonic intraepithelial lymphocytes cultured with or without phytohaemagglutinin (PHA). IntraepitheHal lymphocytes produced low concentrations of gamma-interferon and interleukin-2 when stimulated with PHA, but significantly more than when unstimulated (p < 0.05). There was no difference in production of these cytokines by IEL from control or inflammatory bowel disease.Item The Traeatment of ulcerative colitis : from cure to a new disease(Sri Lanka Medical Association, 1994) de Silva, H.J.